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Abstract
Prenatal immune challenge (PIC) in pregnant rodents produces offspring with abnormalities in behavior, histology, and gene 
expression that are reminiscent of schizophrenia and autism. Based on this, the goal of this article was to review the main 
contributions of PIC models, especially the one using the viral-mimetic particle polyriboinosinic-polyribocytidylic acid (poly-I:C), 
to the understanding of the etiology, biological basis and treatment of schizophrenia. This systematic review consisted of a 
search of available web databases (PubMed, SciELO, LILACS, PsycINFO, and ISI Web of Knowledge) for original studies 
published in the last 10 years (May 2001 to October 2011) concerning animal models of PIC, focusing on those using poly-I:C. 
The results showed that the PIC model with poly-I:C is able to mimic the prodrome and both the positive and negative/cognitive 
dimensions of schizophrenia, depending on the specific gestation time window of the immune challenge. The model resembles 
the neurobiology and etiology of schizophrenia and has good predictive value. In conclusion, this model is a robust tool for the 
identification of novel molecular targets during prenatal life, adolescence and adulthood that might contribute to the development 
of preventive and/or treatment strategies (targeting specific symptoms, i.e., positive or negative/cognitive) for this devastating 
mental disorder, also presenting biosafety as compared to viral infection models. One limitation of this model is the incapacity 
to model the full spectrum of immune responses normally induced by viral exposure.
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Schizophrenia is a devastating lifetime mental illness 
that affects ~0.5-1.0% of the population. The disorder has 
a heterogeneous course and consists of several symptom 
dimensions, namely, positive (hallucinations and delusions), 
negative (e.g., avolition), affective (e.g., depression), and 
cognitive (e.g., memory deficits) (1,2). Schizophrenia is 
responsible for 15% of first medical appointments in psychi-
atric clinics, as well as 30% of the occupation of psychiatric 
wards. The disorder generates high financial costs to health 
services and to society (3-5). 
Epidemiological studies provide compelling evidence 
that perinatal factors, such as exposure to environmental 
insults, including maternal exposure to stress, infections 
and/or immune activation, maternal malnutrition, as well 
as obstetric complications (e.g., hypoxia), confer a high 
attributable risk to schizophrenia (6-8).
According to the classic neurodevelopment hypothesis 
of schizophrenia, relevant genes involved in brain develop-
ment would be susceptible to gene-environment interactions 
- mainly during the second gestational trimester - that would 
lead to disruption of brain development trajectories, limbic 
disorganization and neurochemical (e.g., monoaminergic) 
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imbalances (9,10).
The neurodevelopment theory of schizophrenia receives 
further support from several brain autopsy and neuroimaging 
studies (11-14). Minimal neuronal cytoarchitecture abnor-
malities are observed in the brain of schizophrenia patients, 
with the absence of massive glial proliferation (gliosis), sug-
gesting that damage during brain development contributes 
to the pathophysiology of this particular disorder (15,16). 
Several insults that occur during early neurodevelopment 
phases may impair late postnatal cerebral maturation, 
ultimately leading to an increase in vulnerability to schizo-
phrenia. According to Nestler and Hyman (17), at least four 
elements can play an important role in the postnatal brain 
maturation of schizophrenic individuals: i) maturation of 
GABAergic interneurons; ii) pruning of glutamatergic syn-
apses; iii) maturation of dopaminergic projections (mainly 
mesocortical), and iv) differentiation/myelination of oligo-
dendrocytes. All of these elements are associated with the 
action of novel proteins such as Neuregulin-1 (NRG1) and 
Disrupted-In-Schizophrenia-1 (DISC-1) (17).
Several experimental models are currently available to 
test hypotheses about the pathophysiology of schizophrenia 
(17,18). However, this is a remarkably multifaceted disorder 
with complex clinical presentations that pose significant 
challenges to the development of reliable animal models. 
Therefore, efforts to replicate the schizophrenic syndrome 
in animals are far from complete, leading to a certain degree 
of skepticism in the scientific community (19).
The animal models developed for the study of schizo-
phrenia are: i) drug-induced models (e.g., NMDA receptor 
antagonists - ketamine and apomorphine); ii) lesion-induced 
preparations (e.g., ventral hippocampal lesion); iii) genetic 
(e.g., alpha-CaMKII knockout mice), and iv) neurodevel-
opment approaches (e.g., human influenza virus and rat 
maternal malnutrition).
Recently, research efforts have been directed at the 
development of the so-called neurodevelopment models of 
schizophrenia. Particularly, the prenatal immune challenge 
(PIC) has generated substantial advances in the field, as 
it might longitudinally mimic several behavioral and neu-
robiological aspects of the disorder (20,21). 
The objective of the present study was to perform a 
systematic literature review of relevant articles about PIC 
schizophrenia models and to discuss their main contribu-
tions to the elucidation of the pathophysiology and treatment 
of schizophrenia. Since there is currently a diversity of PIC 
models, we decided to focus on the in vivo model of PIC 
induced by polyriboinosinic-polyribocytidylic acid (poly-I:C), 
investigating its contributions to the understanding of the 
biological bases and treatments of schizophrenia.
Methods
Articles published in English from May 2001 to October 
2011 were searched in relevant web datasets (PubMed, 
SciELO, LILACS, PsycINFO, and ISI Web of Knowledge). 
Search terms included combinations of the following: 
‘schizophrenia and prenatal immune challenge’; ‘prenatal 
immune challenge and animal model’; ‘poly-I:C and schizo-
phrenia’, and ‘schizophrenia and animal model’.
The search covered original articles. However, reference 
lists of reviews and original articles were hand-searched 
for additional references. Conference abstracts were not 
included. Two authors performed the search independently 
(DSM and DPA) and relevant articles were selected by three 
authors (AFC, DSM, and DPA). To prevent biases, inclusion 
criteria were pre-specified as the following: i) development 
of schizophrenia by the administration of poly-I:C injec-
tion during pregnancy in rodents; ii) experimental data of 
at least one endophenotype for schizophrenia (for more 
details, see Gottesman and Gould (22) and Amann et al. 
(23), and iii) inclusion of a control group in the study design. 
The search retrieved 45 articles, 30 of which contemplated 
the inclusion criteria.
To facilitate the discussion of the main findings, this 
article was organized according to the following topics: 1) 
general presentation of the models and their contributions 
to the understanding of the etiology of schizophrenia; 2) 
contributions of the poly-I:C model to the understanding of 
the biological bases of schizophrenia, and 3) contributions 
of the poly-I:C model to the treatment of schizophrenia.
Discussion
General presentation of the models and their 
contributions to the understanding of the 
etiology of schizophrenia
The animal PIC models developed to date are: experi-
mental models of virus exposure, such as human influenza 
(10) and Borna virus (24), as well as those that employ 
cytokine-releasing agents, such as lipopolysaccharide 
(LPS) bacterial endotoxin (25) or the viral mimetic particle 
poly-I:C (26).
The prenatal influenza infection model seems to be 
useful in the investigation of known epidemiological rela-
tionships between exposure to prenatal viral infection and 
the heightened risk of schizophrenia-related psychoses in 
the offspring (27). This model mimics the behavioral and 
morphological changes that follow schizophrenia, since 
it relies on one of the most well-known environmental 
risk factors implicated in its etiology (8,28). The influenza 
infection model has good face and construct validity for 
schizophrenia-like brain and behavioral pathology.
The cytokine-release models were developed to mea-
sure how maternal and/or fetal cytokine imbalance would 
act as core mediators of the association between maternal 
infection and the development of postnatal behavioral and 
cerebral pathology (29). These models are induced through 
the prenatal exposure of animal rodents (female rats or 
mice) in specific gestational stages to diverse immunologic 
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stimuli, such as viruses (24), poly-I:C (30), or LPS (31). Such 
models are having a great impact on the search for pos-
sible neurodevelopmental and neuroimmunologic causes 
of complex human disorders like schizophrenia and autism 
(32). Therefore, PIC models might guide the identification 
of underlying neurobiological mechanisms enrolled in gene-
environment and environment-environment interactions 
relevant to the etiology of schizophrenia (33,34).
Contributions of the poly-I:C model to the 
understanding of the biological bases of schizophrenia 
Poly-I:C is a synthetic analogue of the viral double-
stranded RNA. The injection of this compound leads to the 
activation of pro-inflammatory cytokines for a limited time 
by the activation of Toll-like receptors 3 (TLR3) (35). Thus, 
poly-I:C is a strong interferon (IFN) inducer, mostly of the 
IFN-α and IFN-β types (36,37). The injection of poly-I:C 
mimics the acute phase response to a viral infection 
Animal studies suggest that the prenatal injection of 
poly-I:C elicits subcortical dopaminergic hyperfunction and 
cognitive impairment in the offspring, representing a neu-
rodevelopmental animal model of schizophrenia (38).
Within the spectrum of behavioral changes, prenatal 
poly-I:C injections have been reported to induce severe 
changes in various schizophrenia-related endophenotypes, 
such as: i) sensorimotor gating deficits in adult rat offspring 
(39-41); ii) latent inhibition disruption only in adulthood (42); 
iii) postpubertal emergence of enhanced sensitivity to MK-
801 and amphetamine-induced hyperlocomotion (43,44), 
and iv) morphofunctional alterations in the hippocampus 
and the entorhinal cortex in adult offspring, consistent 
with the well-documented mesolimbic dopaminergic and 
temporolimbic neuropathology of schizophrenia (43). Rats 
injected with poly-I:C develop anxiety-related behaviors, as 
well as impaired object recognition memory (45) and social 
behavior dysfunction, when compared to controls (40). 
The occurrence of behavioral endophenotypes mainly in 
adulthood is consistent with the later onset of schizophrenia 
symptoms seen in clinical settings (46).
Prenatal poly-I:C immune challenges in the middle and 
late gestational phases lead to a quantitative increase in 
mesencephalic dopaminergic neurons in the fetal brain 
(30). This effect is followed by several gene expression 
changes related to the developmental course of dopamin-
ergic neurons, including the sonic hedgehog (ShhN) and 
fibroblastic growth factor 8 (FGF-8), as well as transcrip-
tion factors like nuclear receptor related 1 protein (Nurr1) 
and pituitary homeobox 3 (Pitx3) (30,47). The ShhN and 
FGF-8 genes, as well as the transcription factors Nurr1 
and Pitx3, are essential for the generation, differentiation, 
and maintenance of midbrain dopamine (DA) cells during 
embryonic development (48). 
Recently, following prenatal immune activation, a 
decrease in NMDA receptor function and elevated basal 
extracellular glutamate in the prefrontal cortex was demon-
strated. Together, these are two key features of the NMDA 
glutamate receptor hypofunction model of schizophrenia, 
occurring during late adolescence (49).
Maternal exposure to poly-I:C significantly increased 
tumor necrosis factor-α (TNF-α) protein levels in the mater-
nal plasma and placenta, with no alterations in fetal brain, 
while brain-derived neurotrophic factor (BDNF) and nerve 
growth factor (NGF) levels decreased in the placenta and 
fetal liver/spleen. In the neonatal whole brain, TNF-α was 
decreased while NGF and BDNF were unchanged at 1 and 
7 days after birth (50). These changes represent potential 
mechanisms by which maternal infection can alter neuron 
development and increase the risk for neurodevelopment 
disorders. 
It is important to state that this model allows the rec-
ognition of critical gestational periods of exposure to PIC 
that specifically contribute to the development of postna-
tal changes related to the onset of schizophrenia. The 
gestational period of rodents is 21 days on average. The 
major deficits in pre-pulse inhibition (a behavioral test to 
evaluate sensorimotor gating, one of the most replicated 
schizophrenia endophenotypes) were found mainly in 
animals submitted to PIC on the 9th gestational day (GD9) 
(30,51-53), which is equivalent to an early/middle gesta-
tional exposure.
According to Meyer et al. (20), the early/middle ges-
tational exposure of mice (GD9) impaired sensorimotor 
gating and decreased dopaminergic D1 receptors located 
in the pre-frontal cortex (PFC) of the offspring, whereas the 
exposure in the late gestational phase (GD17) impaired 
working memory and enhanced locomotor changes induced 
by the NMDA receptor antagonist dizocilpine. Furthermore, 
a decrease in the expression of subunit 1 of NMDA hip-
pocampal receptors was found. However, the same study 
has shown that the potentiation of amphetamine-induced 
hyperlocomotion and a reduction of PFC neurons that 
expressed reelin and parvalbumin (GABAergic neurons) 
occurred independently of the prenatal exposure period. 
Such exposure periods correspond to the end of the first 
trimester (GD9) and middle/late phase of the second trimes-
ter (GD17) in humans (54). Thus, these data demonstrate 
that the exposure on GD9 generates phenotypes predomi-
nantly related to positive symptoms, whereas exposure on 
GD15 or GD17 is more suited for the study of behavioral 
correlates of negative/cognitive symptoms, since adult 
offspring also presented histopathological abnormalities 
in the parahippocampal consistent with evidence that this 
is a point at which the parahippocampal region undergoes 
neurogenesis (42,43) and also in the cerebellum (26). A 
retarded myelination and axonal abnormalities in early 
postnatal stages caused by maternal immune activation 
were also detected (55) (Figure 1). 
Available evidence suggests, therefore, that the PIC in 
early/middle gestational phases can lead to dysfunctions 
over multiple neuropsychological domains (e.g., sensorimo-
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tor gating and spatial working memory) (20). This symptom-
atic heterogeneity may be associated with the impairment 
of fundamental neurodevelopmental processes, such as 
cellular proliferation and differentiation triggered by early 
inflammation in the fetal brain, leading to abnormalities in 
subsequent cellular migration, synaptogenesis and matu-
ration of synapses (52,56). Indeed, inflammatory events 
occurring in the initial phase of fetal brain development 
can result in even more severe damage when compared 
to exposure that occurs later in gestation, culminating with 
multiple postnatal dysfunctions and symptomatic heteroge-
neity, as observed in schizophrenia and autism (57).
In addition to the findings of deleterious effects of direct 
inflammatory challenges, results exist showing that healthy 
control animals reared by foster immune-challenged moth-
ers are associated with the occurrence of learning disabilities 
of early and late onset (58). This suggests that maternal 
stress during pregnancy somehow affects postpartum ma-
ternal behavior and underscores the importance of future 
research along this line.
These data suggest that the precise periods of prenatal 
immune challenges influence the susceptibility to distinct 
behavioral and/or cognitive symptoms that emerge in adult 
life and draw attention to the temporal link between PIC and 
the etiology of these disorders (see Table 1).
Contributions of the poly-I:C model to the treatment 
of schizophrenia
Prenatal poly-I:C injection elicits changes similar to those 
observed in schizophrenia that are only fully manifested 
in adult offspring. In rodents, the prepubertal stage - also 
known as periadolescence - can be assessed on postnatal 
days 28-35 (PND28-35), whereas on PND56 the postpuber-
tal period begins (67). Based on the fact that schizophrenia 
symptoms commonly start in late adolescence and early 
adult life, this model might provide a valuable means to 
assess the effects of preventive strategies by the administra-
tion of drugs during the prepubertal period (i.e., prodrome), 
as well as after the complete development of schizophrenia 
symptoms in adult life. In other words, it enables the study 
of preventive and therapeutic approaches to schizophrenia. 
Another highlight of this model is the possibility of studying 
drugs treating the main dimension of schizophrenia, since 
the exposure to the viral particle on GD9 is associated with 
the development of endophenotypes related to positive 
symptoms in the offspring, while the exposure on GD17 can 
be useful to study the negative and cognitive symptoms of 
schizophrenia (20) (Figure 1).
A recently published article has shown that chronic in-
jection of antipsychotics (haloperidol and clozapine) or the 
antidepressant fluoxetine during periadolescence blocked 
the onset of psychotic symptoms in animals predisposed to 
schizophrenia by PIC exposure on GD9. The same study 
revealed several negative influences of early pharmacologi-
cal intervention on normal behavioral development of control 
animals (68). These data suggest that the careful selection 
of at-risk individuals (psychopathologically and genetically) 
is necessary, since preventive treatment of individuals 
without real liability to develop the disorder might result 
in long-lasting deleterious behavioral effects. The admin-
Figure 1. Prenatal exposure to polyriboinosinic-polyribocytidylic acid (poly-I:C) during the early/middle gestational period (gestational 
day 9 - GD9) generates phenotypes related to positive symptoms. The exposure on GD17 (late gestational period) is related to the 
occurrence of behavioral correlates of negative/cognitive symptoms of the disorder.
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istration of risperidone during the periadolescence period 
of animals prevented both ventricular enlargement and 
reduction of hippocampal size in adult offspring, two of the 
most common brain abnormalities observed in schizophre-
nia (69). Risperidone, paliperidone (70), haloperidol (43), 
and clozapine (43,71) prevented the behavioral changes 
observed in adult animals submitted to PIC between GD14 
and GD15, showing that this model predicts responsiveness 
to antipsychotic drugs.
Risperidone and paliperidone treatment beginning 
Table 1. Main contributions of the poly-I:C model to the study of the physiopathology of schizophrenia. 
Reference Gestational day 
challenge
Main behavioral findings Main neurobiological findings
Meyer et al., 2005 (51) 9 Behavioral deficits in adulthood (PPI, LI, 
spatial working memory, enhanced behavioral 
response to amphetamine) 
Increase of IL-10 at 1 and 6 h post-injection, increase 
of IL-1β at 12 h post-injection
Meyer et al., 2006 (57) 6, 9, 13, or 17 GD6, GD9 or GD13 LI deficiency GD17 - elevation of the IL-10/TNF ratio
Meyer et al., 2006 (58) 9 Postpubertal LI disruption, pre- and 
postpubertal loss of LI in control animals 
adopted by poly-I:C-treated surrogate mothers 
-
Fortier et al., 2007 (31) 10-11, 15-16 or 
18-19
No significant effect on PPI -
Smith et al., 2007 (59) 12.5 Co-administration of anti-IL-6 antibody 
prevents the PPI, LI, and exploratory and 
social deficits and normalizes the associated 
changes in gene expression in the brains of 
adult offspring
-
Meyer et al., 2008 (20) 9 or 17 GD9 - impairment of sensorimotor gating; 
GD17 - impairment of working memory, 
potentiation of locomotor reaction to NMDA 
antagonists; time-independent locomotor 
reaction to a dopamine agonist 
GD9 - reduction of prefrontal D1 receptors in adulthood; 
GD17 - reduced hippocampal NMDA-receptor subunit 
expression; time independent reduction in reelin and 
parvalbumin-expressing prefrontal neurons
Meyer et al., 2008 (30) 9 - Increase in the number of mesencephalic dopamine neurons 
in the fetal brain at middle/late gestation; changes in fetal 
expression of genes involved in dopamine neuron generation, 
differentiation and maintenance (ShhN, FGF-8) and 
transcription factors Nurr1 and Pitx3 
Winter et al., 2009 (53) 9 - Increased levels of DA and its major metabolites in the lateral 
globus pallidus and prefrontal cortex in adult brain; decreased 
serotonin in the hippocampus, nucleus accumbens and lateral 
globus pallidus; reduction of taurine in the hippocampus 
Li et al., 2009 (34) 9 or 17 GD9 - disruption in PPI GD9 - enlargement of lateral ventricles in adulthood;
GD17 - expansion of 4th ventricle volume
Li et al., 2010 (60) 9 or 17 - GD9 - alterations in neuronal myelination
Bitanihirwe et al., 2010 (61) 17 Male and female offspring: deficits in social 
interaction, anhedonic behavior, alterations 
in locomotor response to apomorphine. Male 
offspring only: enhanced LI
Sex-specific changes in neurotransmitter levels
Cardon et al., 2010 (62) - Abnormal PPI with delayed appearance found 
in congenitally immune-deficient mice (severe 
combined immune deficient, SCID), reverted 
by immune reconstitution
Impairment of both hippocampal neurogenesis and 
expression of the gene encoding kisspeptin (Kiss1)* 
manifested in adulthood
Dickerson et al., 2010 (63) - Significant reductions in mPFC-HPC EEG 
coherence correlated with decreased prepulse 
inhibition of startle
-
Oh-Nishi et al., 2010 (64) 15 and 17 - Synaptic dysfunction without neuronal loss in the hippocampus 
of juvenile offspring; decreased synaptophysin expression
De Miranda et al., 2010 (65) 16 Impaired neonatal locomotor development 
and abnormal sensorimotor gating responses 
in adult offspring
Inhibited embryonic neuronal stem cell replication and 
population of the superficial layers of the neocortex by 
neurons; effects were dependent on Toll-like receptor 3 (TLR3)
Hsiao and Patterson, 2011 (66) 12.5 - Increased IL-6 mRNA as well as maternally derived IL-6 
protein in the placenta
The table summarizes the main findings using polyriboinosinic-polyribocytidylic acid (poly-I:C) on different gestational days (GD) in ro-
dents and the behavioral and neurochemical pre- and post-natal alterations. PPI = prepulse inhibition of the acoustic startle reflex (i.e., 
reduction of startle reaction to a startle-eliciting stimulus [pulse] when it is shortly preceded by a weak stimulus [prepulse], a measure 
of sensorimotor gating); LI = latent inhibition (i.e., a form of selective associative learning considered to index an organism’s capacity 
to ignore irrelevant stimulus); IL-10 = interleukin-10; IL-1β = interleukin 1-beta; TNF = tumor necrosis factor; ShhN = sonic hedgehog 
gene; FGF-8 = fibroblast growth factor 8; DA = dopamine; Nurr1 = nuclear receptor-related 1 protein; Pitx3 = pituitary homeobox 3; 
HPC = hippocampus; mPFC = medial prefrontal cortex; NMDA = N-methyl-D-aspartate. *Kisspeptin is a protein that triggers the cas-
cade of biochemical changes leading to puberty.
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at the periadolescent period lowered basal glutamate in 
offspring of poly-I:C-treated dams to levels similar to the 
offspring of saline-treated dams (49), also stabilizing the 
response to amphetamine exposure persisting into early 
adulthood (70).
Although more studies are needed to establish the 
real predictive validity of the model, these data raise the 
possibility that, in the near future, the PIC model might 
be a valuable tool to test antipsychotic drugs, as well as 
compounds that might prevent the onset of schizophrenia 
throughout various developmental stages. 
Concluding comments
The PIC models - especially the poly-I:C model discussed 
in further detail in this article - are capable of mimicking 
several aspects of the schizophrenia syndrome in a neurode-
velopmentally oriented approach, reproducing behavioral 
abnormalities as well as some genetic and neurochemical 
alterations present in schizophrenia, which may contribute to 
1) the study of prenatal and postnatal brain dysfunction after 
exposure to immune challenges across different gestational 
stages; 2) provide evidence for the neurodevelopment and 
neuroimmunologic basis of this disorder; 3) enable the study 
of antipsychotic drugs in a preventive (prenatal life and 
prodrome) and therapeutic approach; 4) permit the study 
of medications targeting specific symptoms (i.e., positive 
or negative/cognitive). One advantage of this model is its 
biosafety as compared to viral infection models. The main 
disadvantages of this model are the limited duration of the 
immune response as compared to viral infection models 
and the non-mimicking of the precise immunological insults 
occurring in the human environment. Put differently, it fails 
to model the full spectrum of immune responses normally 
induced by viral exposure.
Thus, the poly-I:C model might open new avenues 
for the identification of novel molecular targets and the 
eventual preclinical development of new treatments for the 
disorder. In particular, the search for effective prevention 
strategies (e.g., at the prodrome) might benefit from the 
use of this model. 
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